Remove 2024 Remove Licensing Remove Marketing Remove Settlement
article thumbnail

Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04

LexBlog IP

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech also announced that it expects to launch AVT04 in Q1 2024 in Canada, May 2024 in Japan, and late July 2024 in the European Economic Area.

article thumbnail

Analysis of February 2024 Delhi High Court Judgment in InterDigital v. Oppo – I

SpicyIP

I provided an overview of the 21 February 2024 Delhi High Court judgment in the earlier post. This post does not, in any manner, get into the arena of willingness or unwillingness of defendants to enter into a licensing agreement. The Court envisaged the completion of trial by the end of 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Parties Settle the Tips v. Wynk Copyright Dispute: Wynk, Wink, and a 12 Crore Nod!

SpicyIP

The latest settlement order dated 18th June 2024, authored by Justice R.I. This case, which has seen several significant rulings over the years, primarily addressed the applicability of statutory licensing vis-a-vis streaming or internet broadcasting. He is interested in intellectual property, AI regulation and tech law.

article thumbnail

SpicyIP Weekly Review (July 1-July 7)

SpicyIP

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?

article thumbnail

Fourth Circuit Issues a Bummer Fair Use Ruling–Philpot v. IJR

Technology & Marketing Law Blog

In 2013, Philpot uploaded the photo to Wikimedia Commons, which is governed by the standard Creative Commons license requiring attribution. Philpot claims his standard photo licensing fee is $3,500, but reuses of the photo from Wikipedia Commons didn’t require any payment (just attribution). ” Market Effect.

article thumbnail

FDA Approves Amgen’s WEZLANA As Biosimilar to and Interchangeable With Janssen’s STELARA (ustekinumab)

LexBlog IP

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. For drugs selected for the first year of the Program, negotiations will end by August 1, 2024.

article thumbnail

SpicyIP Weekly Review (January 22- January 28)

SpicyIP

Do read our summaries of the post on the DHC restraining generic competitors for Ibrunitib, Delhi High Court’s finding on opposition and examination process, and some quick tidbits on the Ram Mandir, Oppo-Nokia dispute settlement, and the Bombay High Court order on Pan cards. Read Yogesh’s post to know more about the judgment!

Music 59